Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flexion Therapeutics Inc    FLXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
17.79(c) 18.08(c) 19.52(c) 20.16(c) 20.59(c) Last
544 386 553 902 1 179 937 1 460 660 805 487 Volume
+3.43% +1.63% +7.96% +3.28% +2.13% Change
More quotes
Financials ($)
Sales 2017 4,32 M
EBIT 2017 -112 M
Net income 2017 -113 M
Finance 2017 266 M
Yield 2017 -
Sales 2018 62,6 M
EBIT 2018 -87,7 M
Net income 2018 -87,4 M
Finance 2018 201 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 89,9x
EV / Sales2018 7,24x
Capitalization 654 M
More Financials
Company
Flexion Therapeutics, Inc. is a pharmaceutical company, which focuses on the development and commercialization of novel, local therapies.The firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis.It offers products under the Zilretta brand.The company... 
More about the company
Surperformance© ratings of Flexion Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEXION THERAPEUTICS INC
06/23 FLEXION THERAPEUTICS, INC. (NASDAQ : FLXN) Files An 8-K Departure of Directors o..
06/23 FLEXION THERAPEUTICS INC : Change in Directors or Principal Officers, Submission..
06/23 FLEXION THERAPEUTICS : Named One of Boston Business Journal's Best Places to Wor..
06/23 Flexion Therapeutics Named One of Boston Business Journal’s Best Places..
06/16 FLEXION THERAPEUTICS : Dai Ichi Life Insurance Company Ltd Takes Position in Fle..
06/12 FLEXION THERAPEUTICS : to Present Data on Zilretta (FX006) at the American Diabe..
06/10 FLEXION THERAPEUTICS : to Present Data on Zilretta™ (FX006) at the America..
06/10 Flexion Therapeutics to Present Data on Zilretta™ (FX006) at the Americ..
05/22 Flexion to Present New Cost-Effectiveness Data on Zilretta™ (FX006) at ..
05/19 FLEXION THERAPEUTICS : Announces Upcoming Data Presentation at the American Diab..
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/23Insider Buying: Flexion Therapeutics, Inc. $FLXN Director Purchases $26,891.6.. 
06/23Flexion Therapeutics Named One of Boston Business Journal’s Best Places to Wo.. 
06/23Flexion Therapeutics : Named One of Boston Business Journal's Best Places to .. 
06/23Flexion Therapeutics Named One of Boston Business Journal’s Best Pl.. 
06/23Flexion Therapeutics, Inc. $FLXN Stock Rating Upgraded by ValuEngine  
More tweets
Qtime:12
News from SeekingAlpha
06/19 MY BIGGEST MISTAKE : Sticking With Gilead Too Long (Bret Jensen)
06/09 2 Small Biotechs That Could Soar In Second Half Of 2017
05/24 BIOTECH FORUM DAILY DIGEST : Medicare Cuts Looming? Spotlight On Invuity
05/22 Economic analysis shows cost effectiveness of Flexion's Zilretta for treating..
05/04 Flexion Therapeutics' (FLXN) CEO Mike Clayman on Q1 2017 Results - Earnings C..
Advertisement
Chart FLEXION THERAPEUTICS INC
Duration : Period :
Flexion Therapeutics Inc Technical Analysis Chart | FLXN | US33938J1060 | 4-Traders
Full-screen chart
Technical analysis trends FLEXION THERAPEUT...
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 35,4 $
Spread / Average Target 72%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael D. Clayman President, Chief Executive Officer, CFO & Director
Patrick J. Mahaffy Chairman
Neil Bodick Chief Scientific Officer
Yamo Deniz Chief Medical Officer
Samuel D. Colella Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
FLEXION THERAPEUTICS I..8.25%654
AMGEN17.98%126 856
CELGENE CORPORATION16.03%104 873
GILEAD SCIENCES-1.52%92 150
REGENERON PHARMACEUTIC..43.43%54 987
VERTEX PHARMACEUTICALS83.97%33 251
More Results